hrp0089p1-p173 | Growth & Syndromes P1 | ESPE2018

Clinical and Radiological Manifestations in a Large Swedish Family with a Pathogenic Heterozygous ACAN Variant

Gkourogianni Alexandra , Segerlund Emma , Hallgrimsdottir Sigrun , Nilsson Ola , Stattin Eva-Lena

Objectives: Heterozygous mutations in the aggrecan gene (ACAN) are associated with idiopathic short stature, with or without advanced bone age (BA), osteochondritis dissecans (OCD) and early onset of severe osteoarthritis (OA). Variable features also include midface hypoplasia, brachydactyly, short thumbs and intervertebral disc degenerative disease.Methods: We reviewed 173 radiographs in 22 individuals (8F:14M), (three shoulders, 10 hands, 10 w...

hrp0095p1-484 | Fat, Metabolism and Obesity | ESPE2022

Suboptimal adherence to statin therapy in children and adolescents with HeFH despite a high therapeutic efficacy: is the cardiovascular risk underestimated?

Bruzzi Patrizia , Di Martino Marianna , Di Caprio Antonella , Filomena Madeo Simona , Lucaccioni Laura , Predieri Barbara , Iughetti Lorenzo

Background: Heterozygous familial hypercholesterolemia (HeFH) is characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease. European guidelines currently support the initiation of statin therapy by age 8-10 years in patients with HeFH to slow the progression of endothelial disfunction and to reduce the risk of cardiovascular disease in adulthood. However, to date, there is lack of data on adheren...

hrp0089p2-p156 | Fat, Metabolism and Obesity P2 | ESPE2018

Pharmacotherapy and the Effects on LDL Levels and Growth in 2 Children with Severe Familial Hypercholesterolemia

Venkatesh Sreedharan Aravind , Yap KP Fabian

Background: Familial Hypercholesterolemia (FH) is an autosomal dominant disorder causing increased levels of total and LDL cholesterol (LDL-C). When onset is in early childhood, it is associated with higher risk of coronary heart disease and hence the emphasis on early identification and strict management to improve the life expectancy. Of the two types of FH, the homozygous variant is the most severe form associated with extremely high levels of LDL.Aim...

hrp0097p1-45 | Diabetes and Insulin | ESPE2023

Common challenges of one uncommon syndrome - single center experience with Congenital Generalized Lipodystrophy

Slavcheva - Prodanova Olga , Archinkova Margarita , Yaneva Natasha , Modeva Iskra , Dimova Ivanka , Savova Radka

Aim: To present some therapeutic difficulties in patients with congenital generalized lipodystrophy (CGL) - a rare autosome recessive disorder characterized by complete absence of adipose tissue. For many years therapy was aimed only at metabolic consequences. In the past few years new pathophysiologic treatment has become available.Methods and materials: We present four girls – currently 25, 22, 16 and 15 years ol...

hrp0086s1.3 | Innovative therapies in bone and mineral metabolism | ESPE2016

Advances in Treatment of Achondroplasia

Legeai-Mallet Laurence

Skeletal development is a temporally-regulated non-linear process orchestrated by a complex genetic network that proceeds via two distinct ossification mechanisms, namely membranous and endochondral ossification. Genetic disorders of the skeletal system affect both bone and cartilage formation from early fetal development up to post-natal growth. Fibroblast growth factor receptor 3 (FGFR3) is an important regulator of bone formation. Achondroplasia is the most common form of d...

hrp0084p3-862 | Fat | ESPE2015

Diagnosis and Treatment of Familial Hypercholesterolemia in Children – A Preliminary Report

Brandt Agnieszka , Bautembach-Minkowska Joanna , Hennig Matylda , Waseg Bartosz , Limon Janusz , Mysliwiec Malgorzata

Background: Heterozygous familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder occuring in 1:500 people. Patients with FH have a high risk of premature cardiovascular diseases. Today effective lipid-lowering therapies are available and it is a chance to extend the life of patients.Aims and objectives: The aim was to analyse the clinical data of children with FH from the Clinic of Pediatrics, Diabetology and Endocrinology and prelim...

hrp0095p2-308 | Late Breaking | ESPE2022

Lal-D: Know it To Recognize it

Paglia Pamela , Valerio Giuliana , Ranucci Giusy , Rosaria Licenziati Maria

Introduction: Lysosomal Acid Lipase Deficiency (LAL-D) is a rare and systemic condition, secondary to LIPA gene mutations, responsible for lysosomal accumulation of cholesterol esters and triglycerides. Clinical manifestations are heterogeneous in terms of age of onset, severity and biochemical and radiological findings. Dyslipidemia, hepatomegaly and hepatosteatosis with hypertransaminasemia are the most common features. There is significant evidence of incre...

hrp0092p2-112 | Fat, Metabolism and Obesity | ESPE2019

Identification of a Novel Heterozygous Missense Mutation in Low-density Lipoprotein Receptor Gene (LDLR) p.(Met652Thr) in an Emirati Family with Familial Hypercholesterolaemia (FH), Observed Genotype-phenotype Correlations and Pharmacotherapeutic Approaches

Al-Olabi Lara , Suliman Sara , Daggag Hinda

Background: Familial Hypercholesterolaemia (FH) is a common autosomal dominant disorder of low-density lipoprotein (LDL) metabolism characterised by elevated levels of plasma LDL-cholesterol (LDL-C), accelerated atherosclerosis and premature cardiovascular disease (CVD). In the Gulf Co-operation Council states, CVD is often diagnosed at a younger age and is the leading cause of mortality. As such, early genetic diagnosis and treatment of FH is important for ri...

hrp0092p3-66 | Diabetes and Insulin | ESPE2019

Familial Hypercholesterolaemia as a Cause of Dyslipidemia in Patient with Type 1 Diabetes

Brandt-Varma Agnieszka , Hennig Matylda , Mysliwiec Malgorzata

Introduction: Diabetes type 1 (DM1) in children can result in lipid disorders due to insulin deficiency. Familial hypercholesterolaemia (FH) is a very common monogenic disorder with occurrence of 1:250 and it may lead to development of cardiovascular disease (CAD) in a very young age.Case report: Female patient with diabetes diagnosed at the age of 5, was referred to joint diabetes and lipid clinic due to high levels of ...

hrp0089p2-p173 | Fat, Metabolism and Obesity P2 | ESPE2018

Familial Hypercholesterolemia Due to Homozygous LDLRAP1 Mutation: Variability of Phenotype and Response to Medical Therapy

Panou Evangelia , Schumacher Johannes , Woelfle Joachim

Background: Familial hypercholesterolemia (FH) leads to markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and is associated with a significantly increased cardiovascular mortality already in childhood and adolescence. FH is caused by dominant mutations in the genes encoding LDL-receptor (LDLR), ApoB-100 and protein convertase subtilin/kexin9 (PCSK9), whereas rarely recessive forms due to mutations in LDL receptor adaptor protein 1 (LDLRAP1...